Sierra Oncology, Inc. (SRRA) Stock on a Roll, Here’s Why

Sierra Oncology, Inc. (SRRA), a late-stage drug development company, closed Tuesday’s regular trading session at $39.52 after gaining an increase of 3.10% during the day. In the premarket, SRRA has surged by 36.26% and as a result, was trading at $53.85 at the time of the writing. GSK to Acquire SRRA The exuberant performance from […]